首页> 美国卫生研究院文献>Mediterranean Journal of Hematology and Infectious Diseases >Acute Panmyelosis with Myelofibrosis - A Rare Subtype of Acute Myeloid Leukemia
【2h】

Acute Panmyelosis with Myelofibrosis - A Rare Subtype of Acute Myeloid Leukemia

机译:急性骨髓炎与骨髓纤维化-急性骨髓性白血病的罕见亚型

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

One case of acute panmyelosis with myelofibrosis (APMF) is here reported. A 45 year old male presented with abrupt onset of rapidly progressing low backache, weakness and pancytopenia. On examination there was no organomegaly. Peripheral blood examination revealed normocytic normochromic red blood cells with 10% circulating blasts. Flowcytometric examination of peripheral blood revealed blasts which were positive for CD34, HLA− DR and myeloid associated antigens (i.e. CD13 and CD33). Blasts were negative for anti MPO. Bone marrow aspirate resulted in a dry tap. Bone marrow biopsy revealed panmyeloid proliferation with scattered blasts which were CD34 positive on imunohistochemistry and negative for anti MPO. Reticulin stain showed grade III myelofibrosis (WHO). Differential diagnosis considered included AML-M7, MDS-RAEB II and AML with myelodysplasia. He was started on chemotherapy [idarubicin and cytarabine; 3+7 induction regimen followed by three cycles of HIDAC (High dose cytosine arabinoside)] after which patient was in complete morphological remission with markedly reduced bone marrow fibrosis. He is now being worked up for allogeneic stem cell transplantation. Patient is asymptomatic at eight months of diagnosis. In conclusion these patients should be managed aggressively with AML therapy and this case report reaffirms the fact that APMF is subtype of AML.
机译:本文报道了1例急性骨髓炎伴骨髓纤维化(APMF)。一名45岁的男性突然出现快速进展的腰酸,无力和全血细胞减少症。经检查,没有器官增大。外周血检查显示血红细胞正常血红细胞具有10%的循环母细胞。对外周血进行流式细胞术检查发现胚泡对CD34,HLA-DR和髓样相关抗原(即CD13和CD33)呈阳性。爆炸对抗MPO呈阴性。骨髓吸出物导致干tap。骨髓活检显示全骨髓细胞增殖,散在的胚细胞在免疫组织化学上呈CD34阳性,而对MPO呈阴性。网状蛋白染色显示III级骨髓纤维化(WHO)。考虑的鉴别诊断包括AML-M7,MDS-RAEB II和伴有骨髓增生异常的AML。他开始接受化疗[伊达比星和阿糖胞苷; 3 + 7诱导方案,然后进行三个周期的HIDAC(高剂量胞嘧啶阿拉伯糖苷)治疗,此后患者处于完全的形态学缓解状态,骨髓纤维化明显减少。他现在正在接受异基因干细胞移植的工作。诊断八个月后,患者无症状。总之,这些患者应积极接受AML治疗,该病例报告重申了APMF是AML的亚型这一事实。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号